Exelixis
EXEL
#1277
Rank
C$24.65 B
Marketcap
C$99.49
Share price
7.70%
Change (1 day)
80.99%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): C$4.60

According to Exelixis's latest financial reports the company's current EPS (TTM) is C$4.60. In 2025 the company made an earnings per share (EPS) of C$4.03.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$4.6013.97%
2025C$4.03
2023C$0.9114.61%
2022C$0.80-22.97%
2021C$1.03100%
2020C$0.52-65.09%
2019C$1.48-53.91%
2018C$3.21333.96%
2017C$0.74-260.61%
2016C-$0.46-58.75%
2015C-$1.12-42.45%
2014C-$1.945.3%
2013C-$1.84

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
C$12.19 164.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
C$1.06-76.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
C$22.63 391.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
C$2.66-42.34%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
C$1.77-61.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
C$6.34 37.58%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
C$4.46-3.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
C-$19.84-530.91%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
C-$1.17-125.45%๐Ÿ‡บ๐Ÿ‡ธ USA